These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28796080)

  • 1. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy.
    Mizoshita T; Katano T; Tanida S; Hirano A; Miyaki T; Ozeki K; Suzuki Y; Sugimura N; Kataoka H; Joh T
    Medicine (Baltimore); 2017 Aug; 96(32):e7800. PubMed ID: 28796080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
    Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
    Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
    Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis.
    Lee YI; Park Y; Park SJ; Kim TI; Kim WH; Cheon JH
    Gut Liver; 2021 Mar; 15(2):232-242. PubMed ID: 32616683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.
    Pouillon L; Baumann C; Rousseau H; Choukour M; Andrianjafy C; Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2019 Apr; 25(5):945-954. PubMed ID: 30329067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1218-1225.e7. PubMed ID: 27913244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis.
    Spoendlin J; Desai RJ; Franklin JM; Glynn RJ; Payne E; Schneeweiss S
    Clin Pharmacol Ther; 2020 Oct; 108(4):874-884. PubMed ID: 32320482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
    Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T
    Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
    Tursi A; Mocci G; Lorenzetti R; Allegretta L; Brandimarte G; Cassieri C; Colucci R; De Medici A; Faggiani R; Ferronato A; Fiorella S; Forti G; Franceschi M; Gallina S; Giorgetti G; Grasso G; Larussa T; Luzza F; Penna A; Pica R; Piergallini S; Porciello S; Pranzo G; Rodino' S; Scorza S; Sebkova L; Zampaletta C; Elisei W; Picchio M
    Eur J Gastroenterol Hepatol; 2021 May; 33(5):670-679. PubMed ID: 33741797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Vedolizumab and Tumor Necrosis Factor Inhibitors in the Treatment of Steroid-refractory Microscopic Colitis: A Systematic Review and Meta-analysis.
    El Hage Chehade N; Ghoneim S; Shah S; Pardi DS; Farraye FA; Francis FF; Hashash JG
    J Clin Gastroenterol; 2024 Sep; 58(8):789-799. PubMed ID: 37668427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.